Clinical trial
A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, OPC Trial
NCT02698852 is registered in ClinicalTrials.gov with Sino Medical Sciences Technology Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, OPC Trial
- Lead sponsor
- Sino Medical Sciences Technology Inc.
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- December 31, 2015
- Completion date
- December 31, 2025
- Enrollment
- 1,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.